The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of estrogen receptor status on EGFR/TP53/CTNNB1 axis in the evolution of non-small cell lung cancer.
 
Yoko Tani
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Kiowa Kirin (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yasuhiro Koh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Hitachi; Kyowa Hakko Kirin; Novartis; Pfizer; Thermo Fisher Scientific; Tosoh Corporation
Consulting or Advisory Role - Tosoh Corporation
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Novartis; On-chip Biotechnologies; TERUMO; Toppan Printing Co.; Tosoh Corporation
 
Akihiro Tamiya
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Pfizer
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kissei Pharmaceutical; Lilly Japan; MSD; Ono Pharmaceutical; Pfizer; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bristol-Myers Squibb; Ono Pharmaceutical
 
Shun-ichi Isa
Research Funding - AstraZeneca
 
Akihito Kubo
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Novartis; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
 
Masahiko Ando
Consulting or Advisory Role - Asahi Kasei
Research Funding - Kyowa Hakko Kirin (Inst)
 
Hideo Saka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyorin; MSD K.K; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)
 
Motohiro Izumi
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Kiowa Kirin (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Koichi Ogawa
No Relationships to Disclose
 
Yoshiya Matsumoto
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Kiowa Kirin (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kenji Sawa
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Kiowa Kirin (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Naoki Yoshimoto
No Relationships to Disclose
 
Tomohiro Suzumura
No Relationships to Disclose
 
Tetsuya Watanabe
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroyasu Kaneda
No Relationships to Disclose
 
Shigeki Mitsuoka
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma (Inst); Kyowa Hakko Kirin; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); lirye Co. Ltd. (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kazuhisa Asai
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tomoya Kawaguchi
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)